Francisco Fonseca

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7138802/publications.pdf

Version: 2024-02-01

50 papers	14,663 citations	331259 21 h-index	168136 53 g-index
56 all docs	56 docs citations	56 times ranked	19735 citing authors

#	Article	IF	Citations
1	Prognostic role of neutrophil-to-lymphocyte ratio in patients with ST-elevation myocardial infarction undergoing to pharmaco-invasive strategy. Cardiovascular Revascularization Medicine, 2022, 34, 99-103.	0.3	6
2	Evaluation of pulse wave velocity and central systolic blood pressure in children and adolescents with chronic kidney disease. Einstein (Sao Paulo, Brazil), 2022, 20, eAO6758.	0.3	2
3	Pacientes NaÃ¯ve Infectados por HIV Apresentam DisfunÃ§Ã£o Concomitante com DiminuiÃ§Ã£o de Anticorpos Naturais contra AutoantÃgenos Derivados da ApolipoproteÃna B Definidos. Arquivos Brasileiros De Cardiologia, 2021, 116, 844-849.	0.3	0
4	Phytosterol consumption and markers of subclinical atherosclerosis: Cross-sectional results from ELSA-Brasil. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 1756-1766.	1.1	4
5	Desempenho do Eletrocardiograma no DiagnÃ³stico da Hipertrofia Ventricular Esquerda em Hipertensos Idosos e Muito Idosos. Arquivos Brasileiros De Cardiologia, 2021, 117, 437-443.	0.3	6
6	AcurÃ¡cia da ReduÃ§Ã£o do Segmento-ST PÃ³s-TrombÃ³lise como Preditor de ReperfusÃ£o Adequada em EstratÃ©gia FÃ¡rmaco-Invasiva. Arquivos Brasileiros De Cardiologia, 2021, 117, 15-25.	0.3	4
7	Evaluation of two highly effective lipid-lowering therapies in subjects with acute myocardial infarction. Scientific Reports, 2021, 11, 15973.	1.6	8
8	Main differences between two highly effective lipid-lowering therapies in subclasses of lipoproteins in patients with acute myocardial infarction. Lipids in Health and Disease, 2021, 20, 124.	1.2	3
9	AtualizaÃ§Ã£o da Diretriz Brasileira de Hipercolesterolemia Familiar â€“ 2021. Arquivos Brasileiros De Cardiologia, 2021, 117, 782-844.	0.3	10
10	Podemos PrÃ©-Tratar Enxertos de Veia com Adiponectina para Melhorar sua Permeabilidade?. Arquivos Brasileiros De Cardiologia, 2021, 117, 1189-1190.	0.3	0
11	The Impact of Advanced Age on Major Cardiovascular Events and Mortality in Patients with ST-Elevation Myocardial Infarction Undergoing a Pharmaco-Invasive Strategy . Clinical Interventions in Aging, 2020, Volume 15, 715-722.	1.3	9
12	Efficacy and Tolerability of a Fixed-Dose Combination of Rosuvastatin and Ezetimibe Compared with a Fixed-Dose Combination of Simvastatin and Ezetimibe in Brazilian Patients with Primary Hypercholesterolemia or Mixed Dyslipidemia: A Multicenter, Randomized Trial. Current Therapeutic Research, 2020, 93, 100595.	0.5	5
13	AusÃªncia de Descenso da PressÃ£o Arterial Detectada pela MonitorizaÃ§Ã£o Ambulatorial da PressÃ£o Arterial em Pacientes com DoenÃ§a de Chagas Aguda Transmitida por Via Oral. Arquivos Brasileiros De Cardiologia, 2020, 114, 711-715.	0.3	2
14	AlteraÃ§Ãµes Precoces nas Interleucinas Circulantes e no Risco InflamatÃ³rio Residual apÃ³s Infarto Agudo do MiocÃ¡rdio. Arquivos Brasileiros De Cardiologia, 2020, 115, 1104-1111.	0.3	8
15	Beneficial effects of green banana biomass consumption in patients with pre-diabetes and type 2 diabetes: a randomised controlled trial. British Journal of Nutrition, 2019, 121, 1365-1375.	1.2	17
16	Capillary electrophoresis with dual diode array detection and tandem mass spectrometry to access cardiovascular biomarkers candidates in human urine: Trimethylamine-N-Oxide and l-carnitine. Journal of Chromatography A, 2019, 1583, 136-142.	1.8	15
17	Circulating microparticles and central blood pressure according to antihypertensive strategy. Clinics, 2019, 74, e1234.	0.6	3
18	Physical Activity and Healthy Eating Patterns in Public Schools in Brazil: A Strategy to Avert Risk Factors in Adulthood. Arquivos Brasileiros De Cardiologia, 2019, 112, 782-783.	0.3	0

#	Article	IF	Citations
19	Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS). European Heart Journal, 2018, 39, 3499-3507.	1.0	375
20	Regional QT Interval Dispersion as an Early Predictor of Reperfusion in Patients with Acute Myocardial Infarction after Fibrinolytic Therapy. Arquivos Brasileiros De Cardiologia, 2018, 112, 20-29.	0.3	6
21	Monocyte subtypes and the CCR2 chemokine receptor in cardiovascular disease. Clinical Science, 2017, 131, 1215-1224.	1.8	123
22	A preliminary study of bipolar disorder type I by mass spectrometry-based serum lipidomics. Psychiatry Research, 2017, 258, 268-273.	1.7	33
23	Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. New England Journal of Medicine, 2017, 377, 1119-1131.	13.9	6,227
24	Statin-associated muscle symptoms: position paper from the Luso-Latin American Consortium. Current Medical Research and Opinion, 2017, 33, 239-251.	0.9	18
25	Effects of four antiplatelet/statin combined strategies on immune and inflammatory responses in patients with acute myocardial infarction undergoing pharmacoinvasive strategy: Design and rationale of the B and T Types of Lymphocytes Evaluation in Acute Myocardial Infarction (BATTLE-AMI) study: study protocol for a randomized controlled trial. Trials, 2017, 18, 601.	0.7	16
26	Challenges Facing the Use of Endothelial Progenitor Cells in Stem Cell Therapies. Critical Reviews in Eukaryotic Gene Expression, 2016, 26, 161-162.	0.4	5
27	Effects of High-Intensity Training of Professional Runners on Myocardial Hypertrophy and Subclinical Atherosclerosis. PLoS ONE, 2016, 11, e0166009.	1.1	7
28	An assessment of oxidized LDL in the lipid profiles of patients with obstructive sleep apnea and its association with both hypertension and dyslipidemia, and the impact of treatment with CPAP. Atherosclerosis, 2015, 241, 342-349.	0.4	18
29	High-intensity statin monotherapy versus moderate-intensity statin plus ezetimibe therapy: Effects on vascular biomarkers. International Journal of Cardiology, 2015, 180, 78-79.	0.8	4
30	Association of nonalcoholic fatty liver disease with cardiovascular risk factors in obese adolescents: The role of interdisciplinary therapy. Journal of Clinical Lipidology, 2014, 8, 265-272.	0.6	35
31	Effects of Ezetimibe on Endothelial Progenitor Cells and Microparticles in High-Risk Patients. Cell Biochemistry and Biophysics, 2014, 70, 687-696.	0.9	21
32	Effects of two lipid lowering therapies on immune responses in hyperlipidemic subjects. Life Sciences, 2014, 98, 83-87.	2.0	9
33	Endothelial Progenitor Cell Mobilization and Platelet Microparticle Release Are Influenced by Clopidogrel Plasma Levels in Stable Coronary Artery Disease. Circulation Journal, 2012, 76, 729-736.	0.7	57
34	Inflammatory environment and immune responses to oxidized LDL are linked to systolic and diastolic blood pressure levels in hypertensive subjects. International Journal of Cardiology, 2012, 157, 131-133.	0.8	8
35	Pharmacokinetic interactions between clopidogrel and rosuvastatin: Effects on vascular protection in subjects with coronary heart disease. International Journal of Cardiology, 2012, 158, 125-129.	0.8	39
36	Race, ethnicity, and the efficacy of rosuvastatin in primary prevention: The Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) trial. American Heart Journal, 2011, 162, 106-114.e2.	1.2	40

#	Article	IF	Citations
37	Sensibilidade do eletrocardiograma na hipertrofia ventricular de acordo com gÃªnero e massa cardÃaca. Arquivos Brasileiros De Cardiologia, 2011, 97, 225-231.	0.3	7
38	Imbalance between endothelial progenitors cells and microparticles in HIV-infected patients naive for antiretroviral therapy. Aids, 2011, 25, 1595-1601.	1.0	48
39	Improvement in HOMA-IR is an independent predictor of reduced carotid intima-media thickness in obese adolescents participating in an interdisciplinary weight-loss program. Hypertension Research, 2011, 34, 232-238.	1.5	36
40	Number Needed to Treat With Rosuvastatin to Prevent First Cardiovascular Events and Death Among Men and Women With Low Low-Density Lipoprotein Cholesterol and Elevated High-Sensitivity C-Reactive Protein. Circulation: Cardiovascular Quality and Outcomes, 2009, 2, 616-623.	0.9	128
41	A Randomized Trial of Rosuvastatin in the Prevention of Venous Thromboembolism. New England Journal of Medicine, 2009, 360, 1851-1861.	13.9	657
42	Primary prevention of vascular events in patients with high levels of C-reactive protein: the JUPITER study. Expert Review of Cardiovascular Therapy, 2009, 7, 1041-1056.	0.6	12
43	High circulating autoantibodies against human oxidized low-density lipoprotein are related to stable and lower titers to unstable clinical situation. Clinica Chimica Acta, 2009, 406, 113-118.	0.5	27
44	Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein. New England Journal of Medicine, 2008, 359, 2195-2207.	13.9	5,712
45	Massa ventricular e critÃ©rios eletrocardiogrÃ¡ficos de hipertrofia: avaliaÃ§Ã£o de um novo escore. Arquivos Brasileiros De Cardiologia, 2008, 90, 249-253.	0.3	13
46	Baseline Characteristics of Participants in the JUPITER Trial, A Randomized Placebo-Controlled Primary Prevention Trial of Statin Therapy Among Individuals With Low Low-Density Lipoprotein Cholesterol and Elevated High-Sensitivity C-Reactive Protein. American Journal of Cardiology, 2007, 100, 1659-1664.	0.7	113
47	The DISCOVERY PENTA study: a DIrect Statin COmparison of LDLâ€Œ Value â€“ an Evaluation of Rosuvastatin therapY compared with atorvastatin. Current Medical Research and Opinion, 2005, 21, 1307-1315.	0.9	30
48	Prevalence of myocardial infarction is related to hyperhomocysteinemia but not influenced by C677T methylenetetrahydrofolate reductase and A2756G methionine synthase polymorphisms in diabetic and non-diabetic subjects. Clinica Chimica Acta, 2005, 355, 165-172.	0.5	33
49	Comparison between the effects of soy milk and non-fat cow milk on lipid profile and lipid peroxidation in patients with primary hypercholesterolemia. Nutrition, 2004, 20, 200-204.	1.1	41
50	Early Benefits of Pravastatin to Experimentally Induced Atherosclerosis. Journal of Cardiovascular Pharmacology, 2002, 39, 389-395.	0.8	12